Fig. 3

The expression level and GSEA analysis of TNFRSF4 and its clinicopathologic significance. A Expression level of TNFRSF4 in the normal and tumor tissues (P < 0.001). B Differential analysis for paired samples to detect the expression of TNFRSF4. Lines connected the dots on behalf of pairs of samples from either normal or tumor tissues from a common patient. C Differential expression of TNFRSF4 of samples, grouped by age. D The correlation of the expression of TNFRSF4 compared among groups classified by pathological grade using the Kruskal Wallis rank-sum test. E Survival probability analysis by DSS for EC patients with different TNFRSF4 expression. Patients were recognized as high or low expression according to the comparison with the median expression level. p = 0.026. F The involved gene sets in HALLMARK collection by the high TNFRSF4 expression sample. The line chart of the upper part represented the enrichment score of the gene sets. Each line described one particular gene set, distinguished by a unique color, and five leading gene sets were displayed in the plot. G The enriched gene sets in HALLMARK by samples with low TNFRSF4 expression. H Enriched gene sets in immunologic signatures by samples of high TNFRSF4 expression. I Enriched gene sets in immunologic signatures by the low TNFRSF4 expression